Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Find generic entry opportunities
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Nasal pharmaceutical compositions|
|Abstract:||A nasal pharmaceutical composition incorporates a non-toxic agent which is capable of increasing the ciliary function e.g. caffeine and at least partially antagonizing the ciliary function depressant effect of the active agent e.g. dihydroergotamine or any other constituent present in the composition.|
|Inventor(s):||Kiechel; Jean-Rene (Rueil-Malmaison, FR), Acezat-Mispelter; Francoise (Elancourt, FR), Plas; Danielle (Rueil-Malmaison, FR)|
|Assignee:||Sandoz Ltd. (Basel, CH)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Formulation; Dosage form; Delivery; Use;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||8202781||Feb 01, 1982|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Denmark||38183||<disabled in preview>|
|Germany||3302949||<disabled in preview>|
|Denmark||164771||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.